Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients.

about

The utilization of next-generation sequencing to detect somatic mutations and predict clinical prognosis of Chinese non-small cell lung cancer patients.

P2860

Q55314072-20E224DD-89B5-4A4A-9286-52D25133A34D

P2860

Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients.

Item

http://www.wikidata.org/entity/Q49720695

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Clinical efficacy and safety o ...... ng cancer in Chinese patients.

@en

Clinical efficacy and safety o ...... ng cancer in Chinese patients.

@nl

type

Item

label

Clinical efficacy and safety o ...... ng cancer in Chinese patients.

@en

Clinical efficacy and safety o ...... ng cancer in Chinese patients.

@nl

prefLabel

Clinical efficacy and safety o ...... ng cancer in Chinese patients.

@en

Clinical efficacy and safety o ...... ng cancer in Chinese patients.

@nl

P1476

Clinical efficacy and safety o ...... ng cancer in Chinese patients.

@en

P2093

Ao-Xiang Guo

http://www.w3.org/2001/XMLSchema#string

Ji-Ye Yin

http://www.w3.org/2001/XMLSchema#string

Jia-Jia Cui

http://www.w3.org/2001/XMLSchema#string

Lei-Yun Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer genome landscapes

A quantitative protein interaction network for the ErbB receptors using protein microarrays

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

P304

529-538

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S136579

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29416353

http://www.w3.org/2001/XMLSchema#string

P932

5790073

http://www.w3.org/2001/XMLSchema#string

Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients.

about

P2860

P2860

Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P932